The performance of companies tied to Viagra's legacy presents a challenging investment landscape. While the initial boom generated substantial returns , generic competition have significantly impacted sales . Investing in connected pharmaceutical firms now requires a discerning assessment of proprietary protection , evolving healthcare shifts , and